Research Analysts Offer Predictions for NRXP Q3 Earnings

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Research analysts at HC Wainwright reduced their Q3 2026 EPS estimates for NRx Pharmaceuticals in a report issued on Tuesday, March 3rd. HC Wainwright analyst P. Trucchio now anticipates that the company will earn $0.03 per share for the quarter, down from their prior estimate of $0.04. HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ FY2030 earnings at $6.15 EPS.

A number of other analysts have also weighed in on the stock. Wall Street Zen upgraded shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 23rd. Zacks Research raised NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday. BTIG Research restated a “buy” rating and set a $25.00 price objective on shares of NRx Pharmaceuticals in a research report on Wednesday, February 18th. D. Boral Capital reiterated a “buy” rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a research report on Tuesday, February 17th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $38.00.

NRx Pharmaceuticals Trading Down 0.3%

Shares of NRx Pharmaceuticals stock opened at $1.80 on Wednesday. The firm’s 50 day moving average is $2.12 and its 200 day moving average is $2.51. The firm has a market capitalization of $57.37 million, a PE ratio of -0.77 and a beta of 1.97. NRx Pharmaceuticals has a 1 year low of $1.58 and a 1 year high of $3.84.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of NRXP. One Wealth Management Investment & Advisory Services LLC increased its stake in shares of NRx Pharmaceuticals by 35.3% in the fourth quarter. One Wealth Management Investment & Advisory Services LLC now owns 37,873 shares of the company’s stock valued at $103,000 after buying an additional 9,882 shares during the period. State Street Corp increased its position in NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock valued at $236,000 after purchasing an additional 10,700 shares during the period. Ethos Financial Group LLC acquired a new stake in NRx Pharmaceuticals during the 3rd quarter valued at approximately $39,000. Sjbenen Advisory LLC bought a new position in NRx Pharmaceuticals during the 4th quarter worth approximately $41,000. Finally, Two Sigma Investments LP lifted its position in shares of NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares during the period. 4.27% of the stock is owned by institutional investors and hedge funds.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.